Last reviewed · How we verify
EuCorVac-19
EuCorVac-19 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens.
EuCorVac-19 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens. Used for COVID-19 prevention in adults.
At a glance
| Generic name | EuCorVac-19 |
|---|---|
| Sponsor | EuBiologics Co.,Ltd |
| Drug class | Recombinant protein subunit vaccine |
| Target | SARS-CoV-2 spike protein (S protein) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
EuCorVac-19 uses recombinant technology to produce SARS-CoV-2 spike protein (S protein) antigens that are administered to trigger both humoral and cellular immune responses. The vaccine is designed to induce neutralizing antibodies and T-cell immunity against the coronavirus, providing protection against COVID-19 infection and severe disease.
Approved indications
- COVID-19 prevention in adults
Common side effects
- Injection site pain or erythema
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older (PHASE3)
- A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults (PHASE3)
- Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |